AN2 Therapeutics Inc (ANTX) Stock Analysis

AN2 Therapeutics Inc (ANTX) is a publicly traded company in the HEALTHCARE sector. It trades at $4.07, carries a market capitalization of $151.63M. This page summarizes the public market data, fundamentals, and frequently asked questions for ANTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

AN2 Therapeutics Inc currently has a Bullish sentiment score of 0.24.

About AN2 Therapeutics Inc

ANTX, or AN2 Therapeutics Inc., is a pioneering biotechnology firm dedicated to advancing innovative therapies for rare and complex diseases, with a strong emphasis on immunology. Based in California, the company is committed to addressing critical unmet medical needs through its state-of-the-art research and development initiatives. AN2 is well-positioned for growth, underpinned by a promising pipeline of therapeutic candidates and strategic collaborations aimed at enhancing patient outcomes...

GNG Research Analysis

GNG Research scores AN2 Therapeutics Inc (ANTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ANTX.

Frequently Asked Questions

Does ANTX pay dividends?

AN2 Therapeutics Inc (ANTX) does not currently pay a regular dividend.

What is ANTX's market cap?

AN2 Therapeutics Inc (ANTX) has a market capitalization of $151.63M with a current stock price of $4.07.